

Docket No.:

2312/2085B (formerly 1440.1027-005)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Raghuram Kalluri

Serial No.:

09/543,371

Filed:

April 4, 2000

Entitled:

Anti-Angiogenic Proteins and

Fragments and Methods of Use Thereof

Examiner:

J. Roark

Group Art Unit:

1644

Conf. No.:

6148

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office using Express Mail to Addressee Service under 37 C.F.R. Section 1.10, Express Mail Label No. EL932822271US on this date, September 11, 2002, postage prepaid, in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, Virginia 22202.

Joyce C. Hersh, Ph.D.

Name of Person Mailing Page

Signature of Person Mailing Paper

U.S. Patent and Trademark Office

Box Sequence

P.O. Box 2327

Arlington, VA 22202

TRANSMITTAL OF FORMAL DRAWINGS

In response to the Office Action mailed on March 12, 2002 in the above-referenced patent application, enclosed please find formal drawings of Figures 18A and 18B on two separate sheets.

Acceptance of the formal drawings is respectfully requested.

Respectfully submitted,

Date:

September 11, 2002

Name: Joyce C. Hersh, Ph.D.

Registration No.: 42,890 Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100

APPROVED O.G. FIG.

BY CLASS SUBCLASS

DRAFTSMAN

Docket/App No.: 1440.1027-005

Title: Anti-Angiogenic Proteins and Fragments and Methods

Inventors: Raghuram Kalluri

FIG. 18A

se Thereof

pET22b(+) forward primer:

5'-CGGGAT <u>CCA GGT TTG AAA GGA AAA CGT</u>-3' (SEQ ID NO:11), pET22b(+) reverse primer:

5'-CCCAAGCTT TCA GTG TCT TTT CTT CAT-3' (SEQ ID NO:12)

cca qqt ttq aaa qqa <u>aaa cgt</u> gga gac agt gga tca cct gca acc tgg aca acg aga ggc ttt gtc ttc acc cga cac agt caa acc aca gca att cct tca tgt cca gag ggg aca gtg cca ctc tac agt ggg ttt tct ttt ctt ttt gta caa gga aat caa cga gcc cac gga caa gac ctt gga act ctt ggc agc tgc ctg cag cga ttt acc aca atg 260. cca ttc tta ttc tgc aat gtc aat gat gta tgt aat ttt gca tct cga aat gat tat tca tac tgg ctg tca aca cca gct ctg atg cca atg aac atg gct ccc att act ggc aga gcc ctt gag cct tat ata age aga tge act gtt tgt gaa ggt eet geg ate gee ata gee gtt cac age caa ace act gae att eet eea tgt eet eae gge tgg att tet etc tgg aaa gga ttt tea tte atc atg tte aca agt gea ggt tct gag ggc acc ggg caa gca ctg gcc tcc cct ggc tcc tgc ctg gaa gaa ttc cga gcc agc cca ttt cta gaa tgt cat gga aga gga acg tgc aac tac tat tca aat tcc tac agt ttc tgg ctg gct tca tta aac cca gaa aga atg ttc aga aag cct att cca tca act gtg aaa gct ggg gaa tta gaa aaa ata ata agt cgc tgt cag gtg tgc atg aag aaa aga cac tga (SEQ ID NO:9)

pET22b-α3(IV) NC1 = nucleotides 4 through 735 Tumstatin 333 = nucleotides 4 through 375 Tumstatin 224 = nucleotides 4 through 375

Tumstatin 334 - nucleotide 376 through 735

APPROVED O.G. FIG.

BY CLASS SUBCLASS

DRAFTSMAN

Docket/App No.: 1440.1027-005

Title: Anti-Angiogenic Proteins and Fragments and Methods of Use entors: Raghuram Kalluri

FIG. 18B

PGL KGK RGD SGS PAT WTT RGF VFT RHS QTT AIP SCP EGT VPL YSG FSF LFV QGN QRA HGQ DLG TLG SCL QRF TTM PFL FCN VND VCN FAS RND YSY WLS TPA LMP MNM API TGR ALE PYI SRC TVC EGP AIA IAV HSQ TTD IPP CPH GWI SLW KGF SFI MFT SAG SEG TGQ ALA SPG SCL EEF RAS PFL ECH GRG TCN YYS NSY SFW LAS LNP ERM FRK PIP STV KAG ELE KII SRC QVC MKK RH (SEQ ID NO:10)

pET22b $\alpha 3$ (IV) NC1 = residues 2 through 245 Tumstatin 333 = residues 2 through 125 Tumstatin 334 = residues 126 through 245